Elite Pharmaceuticals Inc (ELTP)

[Mophron]

The first Prasco shipment revenue was included in yesterday's revenue. They specified that the launch did not happen until January though. So future volume should be higher.
They were adamant that all products were seeing increases and that sales were not flattening.
Purdue litigation was expected and business as usual.
Only guidance given was that full fiscal year revenue will be over 50 million.
4 products under fda review.
Multiple products under r and d but only pr them when/if they pass BE study.
Company is in rapid growth phase.
Facilty expansion going well. Will be good for 5 years.
Someone asked if Nasrat thinks there be Nasdaq uplifting or buyout in 5 years. He said cut that number in half. He seemed pretty confident about this. My opinion but he seemed to have more emphasis when he said "buyout is looking good"